Stocktoria
Traws Pharma, Inc. TRAW
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-07-25
Traws Pharma, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -640.7% | -62997.3% | -8981.4% | -8684.5% | -7299.1% |
| Net margin | 328.7% | -73682.7% | -8384.1% | -8391.2% | -7151.8% |
| FCF margin | — | — | -7940.7% | — | — |
| Return on assets | 86.4% | -667.1% | -83.5% | -48.2% | -29.1% |
| Return on equity | -1457.9% | 526.5% | -177.5% | -67.0% | -35.0% |
| Current ratio | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 |
| Revenue growth | 1134.5% | 0.0% | 0.0% | 0.0% | -2.2% |
Source: SEC EDGAR filings · CIK 0001130598 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.